San Raffaele
Urolithiasis treatment cost in Italy primarily depends on the stone size and surgical approach, with a consultation with a urologist typically ranging from $100 to $300. Key procedures such as ureteral stenting run between $2,800 and $4,800, while specialized laser lithotripsy costs from $3,800 to $6,500. Expenses vary based on clinic tier and medical technology, offering 30-50% savings compared to the US. Top cities for treatment include Milan and Rome.
Typical Urolithiasis Treatment Costs in Italy
Bookimed Expert Insight: For patients requiring complex stone removal, Milan's San Raffaele is a premier choice. As an IRCCS-accredited research hospital, it manages over 52,000 surgical cases annually. For those seeking advanced precision, Ospedale San Carlo di Nancy in Rome provides Da Vinci robotic technology for minimally invasive kidney surgery. This is highly effective for patients needing reconstructive procedures alongside stone clearance.
| Italy | Turkey | Austria | |
| Urethroscopic lithotripsy | from $3,200 | from $1,500 | from $3,200 |
| Ureteral Stenting | from $2,800 | from $1,200 | from $1,800 |
| Laser Lithotripsy | from $3,800 | from $1,800 | from $4,500 |
| Flexible ureterorenoscopy (URS) | from $3,200 | from $2,500 | from $6,000 |
Specializes in minimally invasive techniques for urological conditions, including robotic and laparoscopic surgery at Maria Cecilia Hospital.
Dr. Alessandro Calarco is a skilled urologist with expertise in minimally invasive and endourological procedures. He performs percutaneous lithotripsy, ureterorenoscopy, tumor ablation, and advanced reconstructive surgeries. Dr. Calarco has received international recognition for his clinical work and research. He completed advanced training in Sweden and the UK.
Dr. Calarco graduated with top honors from Università Cattolica del Sacro Cuore in Rome. He completed his Urology specialization and earned a PhD in Oncological Urology at the same university. His research focuses on prostate cancer biomarkers and exosomes. He has also helped develop clinical protocols for hormone-refractory prostate cancer.
He serves as National Head of Urology for SPIGC and is a member of the European Board of Urology. Dr. Calarco holds an international patent for a device that improves percutaneous nephrolithotripsy. He has published extensively and received several awards for surgical innovation and education.